X0306 4 2016-02-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001197032 SMITH IAN F C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP & CFO Common Stock 2016-02-02 4 A 0 17299 0.01 A 125083 D Common Stock 2016-02-03 4 S 0 5000 89.90 D 120083 D Common Stock 2016-02-03 4 S 0 4232 90.97 D 115851 D Common Stock 2016-02-03 4 S 0 1200 91.68 D 114651 D Common Stock 2016-02-03 4 S 0 1652 92.73 D 112999 D Common Stock 5306 I 401(k) Stock Option (Right to Buy) 91.05 2016-02-02 4 A 0 34482 0.00 A 2016-02-01 Common Stock 34482 34482 D Restricted stock unit award that vests in three equal installments on 2/10/2017, 2/10/2018 and 2/10/2019. Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $89.90 (range $89.31 to $90.27). Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $90.97 (range $90.32 to $91.30). Open market sales reported on this line occurred at a weighted average price of $91.68 (range $91.33 to $92.23). Open market sales reported on this line occurred at a weighted average price of $92.73 (range $92.34 to $93.20). The option vests in 16 quarterly installments from 02/02/2016. Omar White, Attorney-In-Fact 2016-02-04